<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0004756'>Ventricular tachycardia</z:hpo> (VT) is a significant therapeutic challenge in patients with <z:mp ids='MP_0001856'>myocarditis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to assess the efficacy and safety of radiofrequency catheter ablation (RFCA) of VT in patients with <z:mp ids='MP_0001856'>myocarditis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: We enrolled 20 patients (15 men; age, 42 [28-52] years) with a history of biopsy-proven <z:mp ids='MP_0001799'>viral</z:mp> <z:mp ids='MP_0001856'>myocarditis</z:mp> and drug-refractory VT; 5 patients presented with electrical storm </plain></SENT>
<SENT sid="3" pm="."><plain>The median left ventricular ejection fraction was 55% (45-60%) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent endocardial RFCA with an irrigated catheter, using contact electroanatomic mapping </plain></SENT>
<SENT sid="5" pm="."><plain>Recurrence of sustained VT after endocardial RFCA was treated with additional epicardial RFCA </plain></SENT>
<SENT sid="6" pm="."><plain>Endocardial RFCA was acutely successful in 14 patients (70%) while in the remaining 6 (30%) clinical VT was successfully ablated by epicardial RFCA </plain></SENT>
<SENT sid="7" pm="."><plain>In 1 patient, <z:e sem="disease" ids="C0948268" disease_type="Disease or Syndrome" abbrv="">hemodynamic instability</z:e> required an intra-aortic balloon pump to complete RFCA </plain></SENT>
<SENT sid="8" pm="."><plain>No major complication occurred during or after RFCA </plain></SENT>
<SENT sid="9" pm="."><plain>Over a median follow-up time of 28 (11-48) months, 18 patients (90%) remained free of sustained VT; 2 patients (10%, both with baseline left ventricular ejection fractionâ‰¤35%) died of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> unrelated to <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In patients with <z:mp ids='MP_0001856'>myocarditis</z:mp>, RFCA of drug-refractory VT is feasible, safe, and effective </plain></SENT>
<SENT sid="11" pm="."><plain>Epicardial RFCA should be considered as an important therapeutic option to increase success rate </plain></SENT>
</text></document>